Breaking News Instant updates and real-time market news.

ELOS

Syneron Medical

07:38
07/17/17
07/17
07:38
07/17/17
07:38

Syneron Medical completes its acquisition and announces management appointments

Syneron Medical announced the successful completion of its acquisition by an affiliate of funds advised by Apax Partners for $11.00 per share in cash in a transaction valued at approximately $400M. As a result of the transaction, Syneron Candela is now a privately held company. Syneron Candela's ordinary shares will cease to trade on The Nasdaq Stock Market before the opening of the market today and will be delisted. In conjunction with the closing of the transaction, Geoffrey Crouse has been appointed CEO and a member of the Board of Directors of Syneron Candela. Crouse has successfully led businesses in the life sciences sector spanning capital equipment, diagnostics and tools. Prior to joining Syneron Candela, he served as CEO of Cord Blood Registry from 2012 to 2015, when the company was sold to AMAG Pharmaceuticals. Prior, he served as COO of Immucor, a publicly traded company in the in-vitro diagnostics marketplace, and led Health Economics and Reimbursement Outcomes for Roche Diagnostics. Also joining Syneron Candela's senior executive team are Mike Johnson as CFO, Mary Trout as President, Americas, and Todd Van Horn as Chief Business Officer. Barclays acted as exclusive financial advisor to Syneron Candela. Gross, Kleinhendler

ELOS Syneron Medical

08/08/16
BMUR
08/08/16
NO CHANGE
Target $13
BMUR
Buy
Syneron Medical revenue decline not a trend change, says Brean Capital
Brean Capital noted Syneron Medical missed Q2 revenue estimates slightly, but beat on non-GAAP earnings. The firm believes the revenue miss was more internal management driven rather than a trend change. Brean Capital said given the stock's depressed valuation and the strong desire of management to turn around the company, they would be buyers of the shares. The firm reiterated its Buy rating and $13 price target on Syneron Medical shares.
02/13/17
LEER
02/13/17
NO CHANGE
LEER
ZELTIQ takeover raises M&A chances for other aesthetic players, says Leerink
After Allergan (AGN) announced an agreement to acquire ZELTIQ Aesthetics (ZLTQ) for $2.475B, Leerink analyst Richard Newitter said he thinks the deal increases the takeover prospects for other aesthetic players, particularly those with non-invasive fat offerings. With ZELTIQ off the table, Cynosure (CYNO), Syneron Medical (ELOS) and Cutera (CUTR) could "move into play for another strategic acquirer relatively quickly," Newitter tells investors. The analyst adds that he views Cynosure as "a much higher quality asset" than Syneron, but adds that the latter is "significantly cheaper." On ZELTIQ, he thinks Allergan is "likely the final suitor" given the price it has agreed to pay.
02/16/17
GRIF
02/16/17
NO CHANGE
Target $14
GRIF
Buy
Syneron Medical price target raised to $14 from $10 at Griffen Securities
Griffen Securities analyst Zack Ajzenman raised his price target for Syneron Medical to $14 saying the Q4 results show the company's Emerging Products group continues to "exhibit traction." The stock remains "significantly discounted," Ajzenman tells investors in a post-earnings research note. He reiterates a Buy rating on Syneron.
05/12/17
MAXM
05/12/17
DOWNGRADE
Target $11
MAXM
Hold
Syneron Medical downgraded to Hold from Buy at Maxim
Maxim analyst Anthony Vendetti downgraded Syneron Medical to Hold from Buy after the company announced the end of the "go-shop" period under its merger agreement with Partners. The analyst, who does not expect a higher competing offer, lowered his price target on Syneron to $11 from $12.

TODAY'S FREE FLY STORIES

IPXL

Impax

$19.95

-0.85 (-4.09%)

07:31
10/17/17
10/17
07:31
10/17/17
07:31
Hot Stocks
Breaking Hot Stocks news story on Impax »

Impax, Amneal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

JBL

Jabil Circuit

$28.61

0.37 (1.31%)

07:31
10/17/17
10/17
07:31
10/17/17
07:31
Recommendations
Jabil Circuit analyst commentary  »

Jabil Circuit strength in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVTCY

Evotec

$51.15

2.3099 (4.73%)

07:31
10/17/17
10/17
07:31
10/17/17
07:31
Conference/Events
Evotec management to meet with Deutsche Bank »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

GPRO

GoPro

$9.08

-0.48 (-5.02%)

, CREE

Cree

$29.28

-0.08 (-0.27%)

07:30
10/17/17
10/17
07:30
10/17/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GPRO

GoPro

$9.08

-0.48 (-5.02%)

CREE

Cree

$29.28

-0.08 (-0.27%)

MT

ArcelorMittal

$28.99

-0.36 (-1.23%)

PXD

Pioneer Natural

$143.69

-0.23 (-0.16%)

BABY

Natus Medical

$39.35

-0.75 (-1.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 25

    Oct

  • 01

    Nov

  • 02

    Nov

CARB

Carbonite

$22.30

-0.5 (-2.19%)

07:30
10/17/17
10/17
07:30
10/17/17
07:30
Initiation
Carbonite initiated  »

Carbonite initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

NEWS

NewStar Financial

$12.13

0.23 (1.93%)

07:30
10/17/17
10/17
07:30
10/17/17
07:30
Hot Stocks
Breaking Hot Stocks news story on NewStar Financial »

NewStar Financial trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JRVR

James River Group

$41.95

-0.08 (-0.19%)

07:27
10/17/17
10/17
07:27
10/17/17
07:27
Initiation
James River Group initiated  »

James River Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

MDB

MongoDB

07:27
10/17/17
10/17
07:27
10/17/17
07:27
Syndicate
MongoDB IPO deal range increased to $20.00-$22.00 »

MongoDB 's 8M share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

NFLX

Netflix

$202.68

3.19 (1.60%)

07:26
10/17/17
10/17
07:26
10/17/17
07:26
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

PSX

Phillips 66

$90.87

-3.56 (-3.77%)

07:26
10/17/17
10/17
07:26
10/17/17
07:26
Recommendations
Phillips 66 analyst commentary  »

Phillips 66 price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

VZ

Verizon

$48.09

0.23 (0.48%)

07:25
10/17/17
10/17
07:25
10/17/17
07:25
Periodicals
Verizon FiOS stops carrying Univision, WSJ reports »

Verizon FiOS has stopped…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

VLO

Valero

$77.42

-0.66 (-0.85%)

07:25
10/17/17
10/17
07:25
10/17/17
07:25
Recommendations
Valero analyst commentary  »

Valero price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

SNDX

Syndax

$12.76

0.39 (3.15%)

07:25
10/17/17
10/17
07:25
10/17/17
07:25
Syndicate
Syndax raises $25M in a registered direct offering »

Syndax announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

07:25
10/17/17
10/17
07:25
10/17/17
07:25
Conference/Events
Immune Design to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 08

    Nov

CVS

CVS Health

$72.44

-0.16 (-0.22%)

07:25
10/17/17
10/17
07:25
10/17/17
07:25
Conference/Events
Economic Club of New York to hold a breakfast meeting »

Larry Merlo, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 20

    Oct

  • 06

    Nov

  • 12

    Dec

CVS

CVS Health

$72.44

-0.16 (-0.22%)

07:25
10/17/17
10/17
07:25
10/17/17
07:25
Conference/Events
Economic Club of New York to hold a breakfast meeting »

Larry Merlo, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 20

    Oct

  • 06

    Nov

  • 12

    Dec

IPXL

Impax

$19.95

-0.85 (-4.09%)

07:24
10/17/17
10/17
07:24
10/17/17
07:24
Hot Stocks
Breaking Hot Stocks news story on Impax »

Impax trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

ANDV

Andeavor

$103.82

-1.55 (-1.47%)

07:24
10/17/17
10/17
07:24
10/17/17
07:24
Recommendations
Andeavor analyst commentary  »

Andeavor price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$30.87

-1.05 (-3.29%)

07:23
10/17/17
10/17
07:23
10/17/17
07:23
Initiation
Tactile Systems initiated  »

Tactile Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

AGN

Allergan

07:22
10/17/17
10/17
07:22
10/17/17
07:22
Recommendations
Allergan analyst commentary  »

Allergan court ruling on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 23

    Oct

  • 01

    Nov

  • 06

    Nov

GRPN

Groupon

$4.70

0.07 (1.51%)

07:22
10/17/17
10/17
07:22
10/17/17
07:22
Initiation
Groupon initiated  »

Groupon initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 16

    Nov

FANG

Diamondback Energy

$102.60

1.23 (1.21%)

07:21
10/17/17
10/17
07:21
10/17/17
07:21
Recommendations
Diamondback Energy analyst commentary  »

Diamondback Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

UNFI

United Natural Foods

$40.57

0.09 (0.22%)

, AMZN

Amazon.com

$1,006.34

3.4 (0.34%)

07:21
10/17/17
10/17
07:21
10/17/17
07:21
Downgrade
United Natural Foods, Amazon.com rating change  »

United Natural Foods…

UNFI

United Natural Foods

$40.57

0.09 (0.22%)

AMZN

Amazon.com

$1,006.34

3.4 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 26

    Oct

07:19
10/17/17
10/17
07:19
10/17/17
07:19
General news
Futures flat following yesterday's advance »

Stock futures are flat…

GM

General Motors

$45.76

-0.12 (-0.26%)

07:19
10/17/17
10/17
07:19
10/17/17
07:19
Periodicals
GM to test self-driving cars in NYC early next year, WSJ reports »

General Motors will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.